Nordic ePharma Day: the trade show
The drug development process as we know it is being transformed through digitalisation.
Increased computing power is allowing new insights through data mining, simulation and artificial intelligence.
Work processes that so far have been handled by humans are starting to be automated, e.g. through robotics processes. All done to minimise cost in the drug development process in form of time and ressources.
While the shorter-term benefits of digitalisation are gradually becoming tangible, there are also longer-term aspirations to transform the entire operating model of clinical research. Consortia like TransCelerate Biopharma, Clinical Trials Transformation Initiative (CTTI) and Innovative Medicines Initiative (IMI) to name a few are putting digitalisation high on the agenda. Digitalisation in form of Shared Investigator Platform, eSource, Digital Data Flow, Technology Enabled Common Protocol Template and Blockchain are seen as major initiatives pulling in big pharma, academic institutions and regulators to jointly transform the way we work – and ultimately change pharma’s role in the broader healthcare perspective.